Tycel Jovelle Phillips, MD, University of Michigan

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.

Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.

Tycel Jovelle Phillips, MD, discusses recent updates from the CHRONOS-3 trial of copanlisib in R/R MZL and clinical implications of the results of this study.

Experts in hematology/oncology discuss second-line and beyond treatment options for patients with MZL and comment on copanlisib monotherapy for the management of R/R MZL as seen in the phase 2 CHRONOS-1 study.

Tycel Jovelle Phillips, MD, and Alexey Danilov, MD, share insights on common signs and symptoms of marginal zone lymphoma and approaching initial therapy.

Dr Tycel Jovelle Phillips reviews key ongoing trials in relapsed/refractory follicular lymphoma.

Expert hematologist-oncologists examine the use of tazemetostat based on a phase 2 trial for relapsed/refractory follicular lymphoma and consider clinical implications.

Dr Alexey Danilov reviews the 2-year follow-up of the phase 2 CHRONOS-1 study evaluating the use of copanlisib monotherapy in relapsed/refractory follicular lymphoma.

Tycel Jovelle Phillps, MD, shares second-line treatment approaches for the management of follicular lymphoma and examines the use of PI3K inhibitors.

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, provide insight on common signs and symptoms of follicular lymphoma (FL) and factors to consider when selecting first-line therapy.

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

Tycel Jovelle Phillips, MD, reviews current therapy options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and how he selects among these options and highlights some potential new therapies.

Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.

Recommendations for mitigating and managing common treatment-related adverse events associated with loncastuximab tesirine based on safety data from LOTIS-2 and variables that may impact patient candidacy.

Potential implications for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with loncastuximab tesirine, an antibody-drug conjugate, based on early results demonstrated by the LOTIS-2 study.

A historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy.

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).